Apogee Therapeutics (APGE) Non-cash Items (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Non-cash Items data on file, last reported at $2.2 million in Q1 2026.

• Non-cash Items for Q1 2026 came in at $2.2 million, up 5404.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 5404.02% YoY), and the FY2025 annual result was $216.2 million, up 251.46% from the prior year.
• Non-cash Items retreated to $2.2 million in Q1 2026 per APGE's latest filing, from $216.2 million in the prior quarter.
• Over five years, Non-cash Items peaked at $216.2 million in Q4 2025 and troughed at $16154.0 in Q4 2023.
• A 4-year average of $28.3 million and a median of $1.3 million in 2023 frame the typical range for Non-cash Items.
• On a YoY basis, Non-cash Items climbed as much as 380647.8% in 2024 and fell as far as 98.22% in 2024.
• A 4-year view of Non-cash Items shows it stood at $16154.0 in 2023, then jumped by 380647.8% to $61.5 million in 2024, then jumped by 251.46% to $216.2 million in 2025, then slumped by 99.0% to $2.2 million in 2026.
• Business Quant data shows APGE's Non-cash Items at $2.2 million in Q1 2026, $216.2 million in Q4 2025, and $43.9 million in Q3 2025.